注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Agenus Inc是一家临床阶段免疫肿瘤学(I-O)公司。它有一系列免疫检查点抗体、过继细胞疗法和新抗原癌症疫苗,用于抗癌。其I-O资产包括基于抗体的疗法、单特异性和双特异性抗体、细胞疗法、疫苗和佐剂。其候选抗体为Balstilimab单抗(一种抗PD-1抗体)和Zalifrelimab单抗(一种抗CTLA-4抗体),该抗体作为二线宫颈癌患者的单一疗法(Balstilimab单抗)和联合疗法(Balstilimab单抗/Zalifrelimab单抗)正在进行2期试验。其临床阶段资产组合还包括Botensilimab(AGNE1181)、AGNE2373、AGNE1423、AGNE1777、MK-4830、INCAGN2390、INCAGN2385和AGNE797。它正在开发个性化的疫苗,即原噬菌体和自噬疫苗,以及现成的疫苗PhosphoSynVax。PhosphoSynVax含有热休克蛋白,可以将新抗原输送到正确的免疫细胞,从而激活抗癌免疫反应。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Marcela V. Maus | - | - | Member of Scientific Advisory Board |
Garo H. Armen | 68 | 1994 | Founder, Executive Chairman & CEO |
Manuel Hidalgo | 53 | - | Member of Scientific Advisory Board |
Daniel D. Von Hoff | - | - | Member of Scientific Advisory Board |
Larry Norton | 76 | 2023 | Member of Advisory Board |
Timothy R. Wright | 65 | 2006 | Independent Lead Director |
Brian J. Corvese | 65 | 2007 | Independent Director |
Robert Benjamin Stein | 72 | 2014 | Member of Advisory Board |
Ulf Arne Wiinberg | 65 | 2016 | Independent Director |
Allison M. Jeynes-Ellis | 57 | 2018 | Independent Director |
Susan B. Hirsch | 70 | 2020 | Independent Director |
Todd Jude Yancey | - | 2023 | Member of Advisory Board & Chief Strategic Advisor |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核